Researcher Spotlight: Harsh Shah, DO The University of Utah Stedman Family Scholar The future of lymphoma treatment is rapidly evolving, and investigator-initiated clinical trials are helping to pave the way toward improved treatment approaches. Dr. Shah’s LRF research is focused…
Researcher Spotlight: Brian Sworder, MD, PhD Stanford University School of Medicine Chimeric antigen receptor (CAR) T cells have shown to be incredibly beneficial for patients with lymphomawho have relapsed after chemotherapy. Unfortunately, however, several patients will still go on to relapse after…
Researcher Spotlight: Patrizia Mondello, MD, PhD Mayo Clinic, Rochester Follicular lymphoma (FL) is generally slow-growing cancerwith an overall favorable prognosis. One subset, known asFL3B, has a distinctly worse clinical outcome with limited treatment options. The same treatments used to manage the other,…
Researcher Spotlight: Tomohiro Aoki, PhD British Columbia Cancer Research Centre Hodgkin lymphoma (HL) treatment relies on multimodality treatment with standard chemotherapy,radiation therapy, and autologous or allogeneic stem celltransplantation in cases of relapsed disease. For his LRFresearch project, Dr. Tomohiro Aoki aims to…
Researcher Spotlight: Erin Mulvey, MD Weill Cornell Medical College Diffuse large B-cell lymphoma (DLBCL) and follicularlymphoma (FL) are the two most common types of non-Hodgkin lymphoma, with one categorized as aggressive (fast-growing) and one considered indolent (slow-growing), respectively.First-line treatment for DLBCL…
Researcher Spotlight: Luis Malpica Castillo, MD The University of Texas M.D. Anderson Cancer Center Adult T-cell leukemia/lymphoma (ATLL) is an aggressive, generally incurable type of non-Hodgkin lymphoma (NHL) caused by infection with the human T-cell leukemia virustype 1 (HTLV-1). This…
Researcher Spotlight: Arushi Khurana, M.B.B.S Mayo Clinic, Rochester, MN More than two-thirds of the newly diagnosed Diffuselarge B-cell lymphoma (DLBCL) patients are excluded from participating in clinical trials, without considering the structural and attitudinal barriers that preclude clinical trial participation. Over the…
Researcher Spotlight: P. Connor Johnson, MD Massachusetts General Hospital Older adults with fast-growing lymphomas are often treated with chemotherapy which has the potential to cure some of these diseases. However, understanding which patientswill have serious side effects, complications, and loss…
Researcher Spotlight: Nicole Prutsch, PhD Dana-Farber Cancer Institute T-cell lymphomas represent a heterogeneous group of peripheral and cutaneous non-Hodgkin lymphomas (NHL) with a range of unmet clinical needs. Anaplastic large cell lymphoma (ALCL) is a CD30+ subtype of non-Hodgkin T-cell…
Researcher Spotlight: Elisa Mandato, PhD Dana-Farber Cancer Institute Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) and the most common hematologic malignancy in the United States. Dr. Mandato’s LRF research project will involve developing…